Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 501Neoplasms 304Breast Neoplasms 298Colorectal Neoplasms 230Neoplasm Metastasis 196Prostatic Neoplasms 175Ovarian Neoplasms 173Lung Neoplasms 160Multiple Myeloma 159Recurrence 134Melanoma 125Pancreatic Neoplasms 116Squamous Cell Carcinoma of Head and Neck 105Stomach Neoplasms 103Leukemia, Myeloid, Acute 102Endometrial Neoplasms 102Small Cell Lung Carcinoma 89Leukemia, Lymphocytic, Chronic, B-Cell 87Triple Negative Breast Neoplasms 85Lymphoma, Non-Hodgkin 85Carcinoma, Renal Cell 83Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 77Lymphoma, Large B-Cell, Diffuse 74Lymphoma, Follicular 68Advanced Solid Tumors 66Parkinson Disease 4, Autosomal Dominant Lewy Body 62Lymphoma 62Glioblastoma 59Head and Neck Neoplasms 57

Interventions

pembrolizumab 1osimertinib 1cemiplimab 1Vascular Endothelial Growth Factor A 1Paroxetine 1Paclitaxel 1Itraconazole 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lethal Congenital Contracture Syndrome 2 × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT07111520 2026-05-05

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

BioNTech SE

Phase 1/2 Recruiting
420 enrolled
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung

NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡